Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 6:26 pm Sale | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 711,967 3.800% | -479,990 (-40.27%) | Filing History |
| 2025-11-14 4:54 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Nantahala Capital Management, LLC | 1,235,000 9.390% | 335,000 (+37.22%) | Filing History |
| 2025-11-14 4:12 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | RA Capital Management, L.P. | 1,386,167 9.900% | 291,760 (+26.66%) | Filing History |
| 2025-11-14 4:11 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 1,053,983 8.000% | 465,351 (+79.06%) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,458,151 9.990% | 419,609 (+40.40%) | Filing History |
| 2025-11-14 2:31 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Caligan Partners LP | 833,333 6.300% | 833,333 (New Position) | Filing History |
| 2025-11-14 12:39 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | SilverArc Capital Management, LLC | 720,922 5.480% | 720,922 (New Position) | Filing History |
| 2025-11-14 08:09 am Sale | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Deep Track Capital, LP | 0 0.000% | -114,775 (Position Closed) | Filing History |
| 2025-11-14 06:01 am Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Balyasny Asset Management L.P. | 817,436 6.220% | 817,436 (New Position) | Filing History |
| 2025-11-13 5:21 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Asset Advisors, LLC | 1,006,217 7.650% | 455,452 (+82.69%) | Filing History |
| 2025-10-30 2:04 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | The Vanguard Group | 692,637 5.260% | 692,637 (New Position) | Filing History |
| 2025-08-27 5:00 pm Unchanged | 2025-08-06 | 13G | Avalo Therapeutics, Inc. AVTX | Patrick J. Crutcher | 549,467 4.200% | 0 (Unchanged) | Filing History |
| 2025-08-14 6:00 pm Unchanged | 2025-06-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 8.900% | 0 (Unchanged) | Filing History |
| 2025-08-05 4:58 pm Purchase | 2025-08-04 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 588,632 5.400% | 586,132 (+23445.28%) | Filing History |
| 2025-05-15 5:33 pm Purchase | 2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 1,191,957 9.990% | 221,598 (+22.84%) | Filing History |
| 2025-05-15 4:49 pm Purchase | 2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX | RA Capital Management, L.P. | 1,094,407 9.900% | 127,108 (+13.14%) | Filing History |
| 2025-05-15 4:36 pm Purchase | 2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX | Nantahala Capital Management, LLC | 900,000 8.430% | 900,000 (New Position) | Filing History |
| 2025-02-14 4:02 pm Purchase | 2024-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,038,542 9.990% | 71,243 (+7.37%) | Filing History |
| 2024-12-31 4:13 pm Purchase | 2024-12-23 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Asset Advisors, LLC | 550,765 5.300% | 550,765 (New Position) | Filing History |
| 2024-11-14 6:23 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 9.900% | 967,000 (New Position) | Filing History |